Whalesbook
Q4 Performance Falls Short
Cipla's fourth-quarter fiscal year 2026 performance fell short of market expectations. Revenue for the quarter declined by 3% year-over-year to ₹6,541.20 crore, while net earnings dropped 55% to ₹554.60 crore. EBITDA also saw a significant drop of 35% to ₹997 crore. These results were released on May 14, 2026. The company's stock saw an immediate positive reaction, trading up 8.05% to ₹1,434.00 on the announcement day, though it had declined 7.4% over the preceding five trading days. Cipla's market capitalization stood between ₹1.05 trillion and ₹1.15 trillion in mid-May 2026, with its trailing twelve-month P/E ratio fluctuating around 23-25x. This valuation places it between peers like Dr. Reddy's Laboratories (P/E ~19.39) and Sun Pharmaceutical Industries (P/E ~40.31).
Regional Performance and Margin Squeeze
Growth in key markets like India and Africa offered some support. India expanded by a robust 15% year-over-year, boosted by in-licensing deals for products including Eli Lilly's obesity drug and Pfizer products such as Corex, Dolonex, and Neksium. These in-licensed assets collectively contributed an estimated 400-500 basis points to this growth. However, the North American market saw a substantial 26% drop. This decline was primarily due to the loss of high-margin products like gRevlimid and the discontinuation of lanreotide. This regional performance highlights dependence on specific product cycles for growth momentum.
Cipla's EBITDA margins narrowed by 760 basis points year-over-year, closing at 15.2% from 22.8% in the prior year's quarter. This compression resulted from the reduced contribution of high-value legacy products and a planned increase in research and development (R&D) expenditure. R&D costs rose by 20% year-over-year, increasing to 7.8% of sales from 6.3% in Q4 FY25. While crucial for long-term growth, these increased R&D investments are a near-term drag on profitability.
Investor Concerns and Competitive Landscape
Despite analyst recommendations often leaning towards 'Buy' or 'Hold', investor concerns are significant. The sharp 55% year-over-year decline in net profit, alongside margin compression and higher R&D spending, points to substantial operational pressure. The contraction in the North American market, caused by losing key products, reveals vulnerability to product lifecycles and generic competition. Cipla's ambitious US revenue targets depend heavily on upcoming launches like gVentolin, gAdvair, and teduglutide. However, a neutral consensus rating and mixed analyst views temper the outlook. Nirmal Bang downgraded its rating to 'Hold', and MarketsMojo issued a 'Sell' rating, reflecting worries about maintaining growth and profitability amidst rising costs and competition.
Outlook and US Growth Strategy
Looking ahead, Cipla anticipates full-year EBITDA margins to range between 18.5% and 20%, with expected improvement in the second half of the fiscal year driven by its US operations. The company projects its US revenue run rate to reach approximately $250 million by the fourth quarter of fiscal year 2027, up from $155 million currently. While some analysts maintain 'Buy' ratings with price targets around ₹1,700, recent downgrades to 'Hold' and 'Sell' ratings temper this optimism. Cipla's future financial performance will hinge on successfully executing its new US product launches, managing R&D expenditures, and navigating pricing pressures in key markets.